Florida Atlantic University’s Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer’s disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies.
from Dementia Big http://ift.tt/1Sgs3qW via alcoholic dementia
http://ift.tt/214IhG2
No comments:
Post a Comment